Insider buying last 90 days
No open-market insider purchases were filed for CRNX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every CRNX insider filing, plotted on the chart in Gekko.Open CRNX in Gekko
No recent trading data for CRNX. The last close Gekko holds is Aug 31, 2026, so the figures on this page may be out of date.
NASDAQ: CRNX
Crinetics Pharmaceuticals (CRNX) Stock Analysis & Forecast
Aug 31 close
$84.95+0.11 (+0.1%)
Gekko Brief
Crinetics Pharmaceuticals closed at $84.95 on 31 August 2026, +0.1% on the day. The price sits above both the 50-day ($74.83) and 200-day ($50.44) moving averages, inside a 52-week range of $30.25 to $85.01. The GekkoIndex reads 37.7, in the Distribution zone, down 0.8 points over five sessions. Gekko Fair Value is $81.44, so the price is 4.3% above it.
The next earnings report is due on 5 November 2026, 37 days away (after close). Over the last 8 reports the company beat the earnings estimate 2 times, with an average move of 5.3% across the report. Seasonally, the next 20 trading days from this point averaged +4.3% over the last 5 years, rising in 3 of them.
14 firms rate the stock: 2 buy, 12 hold and 0 sell, with a consensus target of $85.00. A typical daily move is about 0.2%, and a typical 20-day move about 8.5%. On the swing-trade checklist, 3 items read supportive and 1 reads as a headwind (gekkoindex).
Generated Sep 29, 2026 from the data above.
Crinetics Pharmaceuticals price vs fair value
Close $84.95200-day averageGekko Fair Value $81.44
Crinetics Pharmaceuticals quick facts
- Market cap
- $9.00B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$5.05
- Revenue, TTM
- $42.16M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.09
- Volume
- 8.21M avg 2.57M
- 1-year return
- +177.2%
- Typical daily move
- ±0.2%
- Typical 20-day move
- ±8.5%
- 50-day average
- $74.83
- 200-day average
- $50.44
- Next earnings
- Nov 5 after close
- Shares outstanding
- 106.1M
Crinetics Pharmaceuticals swing-trade checklist
Crinetics Pharmaceuticals scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $84.95 is above the 50-day ($74.83) and 200-day ($50.44) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexheadwind
37.7, Distribution
Reading 37.7 is in the Distribution zone.
See the GekkoIndex - Fair valuemixed
4.3% above
Price is within 5% of Gekko Fair Value (4.3% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 37 days
Next report Nov 5, 2026, 37 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+4.3% on average
From this point in the calendar, the next 20 trading days averaged +4.3% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Crinetics Pharmaceuticals stock chart and price history
Crinetics Pharmaceuticals closed at $84.95 on Aug 31, 2026, +177.2% over the past year, inside a 52-week range of $30.25 to $85.01.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +1.7%
- 3 months
- +146.1%
- 6 months
- +108.8%
- 1 year
- +177.2%
The full CRNX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CRNX in Gekko
Follow Crinetics Pharmaceuticals through every session
Put CRNX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track CRNX in GekkoFree for 7 days. No credit card required.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals develops treatment candidates for rare disorders of the endocrine system and related tumors, working at the clinical trial stage rather than selling approved products. Its most advanced candidate, Paltusotine, is a pill taken by mouth that targets a specific somatostatin receptor and has finished Phase III testing for acromegaly, alongside completed Phase II work in carcinoid syndrome and nonfunctional neuroendocrine tumors.
Beyond its lead candidate, the company is testing two other oral compounds in early clinical trials. CRN04777 acts on a different somatostatin receptor and is being studied in Phase I for congenital hyperinsulinism, while CRN04894 blocks a hormone linked to adrenal function and is in Phase I trials for Cushing's disease and congenital adrenal hyperplasia. Its work centers on developing these therapies through clinical stages toward possible future approval.
Crinetics Pharmaceuticals was founded in 2008 and is headquartered in San Diego, California. Its shares are listed on the NASDAQ under the ticker CRNX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- crinetics.com
Crinetics Pharmaceuticals GekkoIndex: the smart money zone
Crinetics Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 37.7, in the Distribution zone, down 0.8 points over five sessions.
37.7Distribution
Down 0.8 points over five sessions.
Reading for Aug 31, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 48 | +0.9% | +1.9% | ||
| Accumulation | 195 | +0.4% | +5.3% | ||
| Neutral | 358 | +1.3% | +5.2% | ||
| Distribution (current zone) | 46 | +4.0% | +4.0% | ||
| Selling | 7 | Too few readings yet | |||
Average CRNX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
See every daily GekkoIndex reading plotted over the CRNX price, zone by zone.Track CRNX in Gekko
Is Crinetics Pharmaceuticals stock overvalued? Gekko Fair Value
Crinetics Pharmaceuticals trades 4.3% above Gekko Fair Value of $81.44, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Crinetics Pharmaceuticals shares are worth, recalculated every trading day.
$81.44
Gekko Fair Value, Sep 9, 2026
4.3% above fair value · About fair value
Gekko Fair Value on every chart, with the gap to price updating daily.Open CRNX in Gekko
Crinetics Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Crinetics Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in CRNX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for CRNX, plotted on the chart in Gekko.Open CRNX in Gekko
Buybacks
Crinetics Pharmaceuticals has been buying back its own shares.
- Bought back, year ended Dec 31, 2019
- $59K
- As a share of market cap
- 0.00%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold CRNX.
0added0opened0trimmed2sold out
Which funds are on each side, name by name.Unlock in Gekko
Crinetics Pharmaceuticals earnings: next date and track record
Crinetics Pharmaceuticals reports on Nov 5, 2026, after the close (37 days away), and beat the EPS estimate in 2 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected after the close, 37 days away
- EPS estimate
- −$1.20
- Revenue estimate
- $21.04M
2 of 8reports beat the EPS estimate
±5.3%average move across the report
1 of 8reports followed by a gain
Share-price move across each report
Last earnings call, May 7, 2026 AI summary
- What they said
- Crinetics reported a strong Q1 2026 driven by the commercial launch of Palsonify and continued advancement of its clinical pipeline. Management highlighted 232 new patient enrollment forms and $10.3M in net product revenue from Palsonify, broadening uptake across treatment-experienced and increasing treatment-naive patients (15% in Q1). The company emphasized robust pipeline activity (multiple Phase II/III and Phase III trials enrolling), a favorable safety profile across programs, and a solid balance sheet ($1.3B cash) while maintaining 2026 GAAP and non-GAAP operating expense guidance. Management conveyed confidence in launch momentum, market access progress (approximately 70% reimbursement coverage early in launch), and ongoing efforts to accelerate clinical trial enrollment, while noting standard regulatory, reimbursement and timing uncertainties.
- Guidance
- Management stated they are maintaining their 2026 GAAP and non-GAAP operating expense guidance. They do not provide revenue guidance for Palsonify this year and do not expect meaningful international revenue in 2026; they are prepared for early international launches in 2027. No other explicit financial forecasts were issued.
- Risks flagged
- Forward-looking statements and uncertainties described in SEC filings; potential headwinds include regulatory and reimbursement uncertainty (particularly international pricing/access), variability in patient appointment timing impacting starts, the pace of clinical trial enrollment and site activation, potential safety signals that would affect trials (though none identified to date), and macro/market factors that could affect uptake.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| May 7, 2026 | −$1.23 est −$1.20 | $10.73M est $8.51M | −10.1% |
| Feb 26, 2026 | −$1.29 est −$1.37 | $6.16M est $4.49M | −5.3% |
| Nov 6, 2025 | −$1.38 est −$1.27 | $143K est $4.32M | −5.9% |
| Aug 7, 2025 | −$1.23 est −$1.13 | $1.03M est $394K | −5.9% |
| May 8, 2025 | −$1.04 est −$0.95 | $361K est $348K | −2.3% |
| Feb 27, 2025 | −$0.88 est −$0.89 | — est $727K | +9.9% |
| Nov 12, 2024 | −$0.96 est −$0.91 | — est $218K | −1.8% |
| Aug 8, 2024 | −$0.94 est −$0.86 | $399K est $510K | −1.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Crinetics Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Crinetics Pharmaceuticals is $85.00, +0.1% from the last close, from 14 firms rating the stock in the last 90 days.
$85.00consensus 12-month target, +0.1% from the last close
Now $84.95Avg $85.00
Low $80High $95
Each firm’s latest rating in the last 90 days: 14 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 11 | H.C. Wainwright | $85 | +0.1% |
| Jul 28 | UBS | $85 | +0.1% |
| Jul 27 | UBS | $85 | +0.1% |
| Jul 11 | LifeSci Capital | $85 | +0.1% |
| Jul 8 | Stifel Nicolaus | $85 | +0.1% |
+4.0%average 20-day move after past Distribution readings
+4.3%average move over the next 20 trading days in the last 5 years
±0.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Crinetics Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Crinetics Pharmaceuticals averaged +4.3% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −4.3% | 1 of 5 |
| Next 10 trading days | −1.2% | 2 of 5 |
| Next 15 trading days | −0.8% | 1 of 5 |
| Next 20 trading days | +4.3% | 3 of 5 |
| Next 30 trading days | +6.7% | 2 of 5 |
For scale, CRNX’s typical 20-trading-day move in either direction is about 8.5%.
Crinetics Pharmaceuticals market cap and key statistics
Crinetics Pharmaceuticals’s market cap is $9.00B and revenue of $42.16M over the last twelve months.
Valuation
- Market cap
- $9.00B
- EPS, TTM
- −$5.05
- Gekko Fair Value
- $81.44
Trading
- Volume
- 8.21M
- Avg volume, 20 days
- 2.57M
- 52-week high
- $85.01
- 52-week low
- $30.25
- Shares outstanding
- 106.1M
Financials
- Revenue, TTM
- $42.16M
- Profit margin
- 0%
- Return on equity
- -42.4%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.09
- Typical daily move
- ±0.2%
- Typical 20-day move
- ±8.5%
Crinetics Pharmaceuticals stock news this week
Coverage of Crinetics Pharmaceuticals this week reads neutral: 1 positive, 2 neutral and 1 negative headlines.
- Financial Comparison: Crinetics Pharmaceuticals (NASDAQ:CRNX) and Lyra Therapeutics (OTCMKTS:LYRA)Defense World, Sep 21
- Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership TeamInvesting News Network, Sep 1
- BlackRock Inc. Purchases New Position in Crinetics Pharmaceuticals, Inc. $CRNXDefense World, Aug 26
- AWM Investment Company Inc. Invests $3.18 Million in Crinetics Pharmaceuticals, Inc. $CRNXDefense World, Aug 26
- Crinetics (NASDAQ: CRNX) CFO now holds 79,427 shares after RSU grantStock Titan, Aug 25
- Crinetics Pharmaceuticals stock hits all-time high at 84.8 USD By Investing.comInvesting.com Canada, Aug 24
Crinetics Pharmaceuticals peers
Crinetics Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Crinetics Pharmaceuticals stock FAQ
What is Crinetics Pharmaceuticals’s market cap?
Crinetics Pharmaceuticals’s market cap is $9.00B at the Aug 31, 2026 close of $84.95, with 106.1M shares outstanding.
What is the Crinetics Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Crinetics Pharmaceuticals is $85.00, +0.1% from the last close. Of the 14 firms that rated the stock in the last 90 days, 2 rate it a buy, 12 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Crinetics Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Crinetics Pharmaceuticals is about fair value: the Aug 31, 2026 close of $84.95 is 4.3% above Gekko Fair Value of $81.44. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Crinetics Pharmaceuticals report earnings next?
Crinetics Pharmaceuticals is expected to report on Nov 5, 2026, after the market closes (37 days away). Analysts expect earnings of −$1.20 per share on revenue of $21.04M. Crinetics Pharmaceuticals beat the earnings estimate in 2 of its last 8 reports, moving 5.3% on average across the report.
What is Crinetics Pharmaceuticals’s 52-week high and low?
Crinetics Pharmaceuticals’s 52-week high is $85.01 and its 52-week low is $30.25; it closed at $84.95 on Aug 31, 2026, +177.2% over the past year.
Is Crinetics Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 1 as mixed (fair value) and 1 as a headwind (gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Crinetics Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.